The Legal Examiner Affiliate Network The Legal Examiner The Legal Examiner The Legal Examiner search instagram avvo phone envelope checkmark mail-reply spinner error close The Legal Examiner The Legal Examiner The Legal Examiner
Skip to main content

Bayer Corporation failed to share data on the risks of Trasylol with the FDA. Trasylol is a drug that slows or prevents bleeding and is often used in heart surgery. The data came from a retrospective study, done for Bayer by a contract research organization, suggesting an increased risk of death, kidney damage, heart failure and strokes with the use of Trasylol. Bayer did not provide the information to the FDA at a September 21 public meeting, and a few days later the FDA received a tip about the data. Bayer said that its action was “a mistake on the company’s part.”

Comments for this article are closed.